A dvances in gene delivery techniques together with an improved understanding of cytokine biology have led to the concept of cancer vaccination with genetically engineered tumor cells expressing cytokines. Although systemic administration of cytokines has a very limited efficiency because of severe toxicity and low local concentrations, peritumoral secretion of a cytokine can alter the local immunological environment without inducing damaging effects.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) has been described as the most potent specific and long-lasting inducer of antitumoral immunity in a B16 melanoma model. 1 Several groups suggested that the effect of local production of GM-CSF may be related to its ability to induce the differentiation of the hematopoietic precursors into professional antigen-presenting cells (APCs). [2] [3] [4] [5] [6] In different models, GM-CSF gene transfer enhanced immunogenicity and abolished 7, 8 or decreased the tumorigenicity of cells implanted into syngeneic host animals. 3, 9 In the neuroblastoma C 1300 model, inoculation of wild-type cells into the mice that had rejected GM-CSF-producing cells did not generate any tumors, thus indicating a systemic antitumoral immunity. 8 Other studies demonstrated that subcutaneous vaccination with irradiated GM-CSF-producing tumor cells could also protect against challenge with parental tumoral cells in the B16 1, 10, 11 or the HFH18 melanoma models. 2 Interleukin-12 (IL-12) is a heterodimeric cytokine that has potent effects on innate and adaptive immunity. It induces interferon-␥ secretion by T cells and natural killer (NK) cells, increases the cytolytic activity of cytotoxic T lymphocytes (CTLs) and NK cells, and supports the differentiation of T helper 1 (Th1) effector cells. IL-12 stimulates the in vitro antitumoral activity of the lymphocytes of cancer patients as well as in vivo antitumoral activity in many murine tumor models.
12-14 IL-12 gene transfer in NXS2 neuroblastoma cells, 15 MT901 mammary carcinoma cells, 9 and MCA207 sarcoma cells 16 resulted in a complete loss of tumorigenicity with or without induction of protection against challenge with wild-type tumor cells. 9, 15, 16 Several investigators also demonstrated that the decrease of tumorigenicity was directly correlated with the amounts of IL-12 produced by the cells. 17, 18 We used retroviral vectors to express murine GM-CSF (mGM-CSF) or murine IL-12 (mIL-12) in DHD/ K12 Prob cells. DHD/K12 are poorly immunogenic, 19, 20 and immunosuppression has even been described in DHD/K12 tumor-bearing hosts. 21, 22 We subsequently determined whether intraperitoneal (i.p.) vaccination with live or irradiated syngeneic tumor cells producing GM-CSF or IL-12 could generate an effective antitumoral immune response against parental tumors. Our results showed that IL-12-or GM-CSF-engineered DHD/K12 Prob cells lost tumorigenicity and partially protected BDIX rats against a subsequent i.p. challenge with DHD/K12 parental cells.
MATERIALS AND METHODS

Animals and cell lines
Eight-week-old male and female syngeneic BDIX rats were purchased from Iffa-Credo (L'Arbresle, France).
DHD/K12 Prob cells were cultured in Dulbecco's modified Eagle's medium (Life Technologies, Gaithersburg, Md) supplemented with 5% fetal bovine sera (FBS), 1% glutamine (200 mM), 1% N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (1 M), 1% arginine (0.55 mM), penicillin (100 IU/mL), and streptomycin (100 g/mL).
FLYA13 packaging cells were cultured in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% FBS, 1% glutamine (200 mM), penicillin (100 IU/mL), and streptomycin (100 g/mL).
UMR 106-01 cells (osteosarcoma cell line from SpragueDawley rats) 23, 24 were cultured in Eagle's minimum essential medium (Life Technologies) supplemented with 10% FBS, 2% N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (1 M), 1% nonessential amino acids (100ϫ), 1% sodium pyruvate (100 mM), 1% glutamine (200 mM), penicillin (100 IU/mL), and streptomycin (100 g/mL).
Retroviral vectors, infection, and transfection
The BAG retroviral vector, derived from a murine retrovirus (Moloney murine leukemia virus (MoMuLV)), was a generous gift of Dr. C.-M. Calberg (Laboratory of Virology, University of Liège, Liège, Belgium). This vector contains the lacZ gene driven by the first long terminal repeat and the neomycin resistance gene driven by the simian virus 40 promoter.
In the mGM-CSF and mIL-12 retroviral vectors (MoMuLV), mGM-CSF or mIL-12 genes were expressed under the control of the first long terminal repeat and the neomycin resistance gene was driven by a simian virus 40 promoter. The mGM-CSF coding sequence was amplified by polymerase chain reaction (PCR) from the pCDNA1 mGM-CSF plasmid using a sense (5Ј) BamHI primer (5Ј-TATA/GGATCC/CTA-AGGTCCTGAGGAGGATG) and an antisense (3Ј) BamHI primer (3Ј-TATA/GGATCC/AGCTGGCCTGGGCTTC-CTCA). The PCR product (500 bp) was inserted at the BamHI-BamHI sites of the BAG retroviral vector. The mIL-12 coding sequence was amplified by PCR from the pCDNA1 mIL-12 plasmid using a sense 5Ј BamHI primer (5Ј-TATA/ GGATCC/TCGCAGCAAAGCAAGATGTG) and an antisense (3Ј) BamHI primer (3Ј-ATAT/GGATCC/TTCAGGCG-GAGCTCAGATAG). The PCR product (2400 bp) was inserted at the BamHI-BamHI sites of the BAG vector. pCDNA1 mGM-CSF and pCDNA1 mIL-12 expression vectors were generous gifts of Prof. K. Thielemans (Laboratory of Hematology and Immunology, Vrije Universiteit Brussels, Brussels, Belgium).
The integrity of the mGM-CSF and mIL-12 p40 and p35 DNA sequences was confirmed by DNA sequencing.
IL-12 and GM-CSF retroviral vectors were transfected in the FLYA13 packaging cell line by lipofection (N-(1-[2,3-dioleoyloxy]propyl)-N,N,N-trimethylammonium methylsulfate; Roche, Germany). Colonies were isolated by G418 selection (geneticin: active concentration of 0.5 mg/mL) and expanded. Cell-free supernatants were tested for viral titers and used to infect DHD/K12 Prob cells as described previously for DHD/K12 thymidine kinase (TK) cells. 25 Stably transfected DHD/K12 IL-12 and DHD/K12 GM-CSF cells were obtained by G418 selection.
Cytokine assays
The secretion of mIL-12 and mGM-CSF by liposome-transfected packaging cells was determined by enzyme-linked immunosorbent assay (ELISA) using a Quantiquine ELISA kit (R&D Systems, Minneapolis, Minn) for detection of mGM-CSF and an Intertest-12x ELISA kit (Genzyme, Cambridge, Mass) for quantification of mIL-12 p70.
Briefly, 10 6 transduced cells were plated in 25-cm 2 T flasks with 5 mL of culture media supplemented by G418 (0.5 mg/mL). After 48 hours, supernatants were centrifuged and tested for mIL-12 or mGM-CSF production by ELISA; results are expressed as ng/10 6 cells/48 hours.
In vivo injection of IL-12-or GM-CSF-transduced cells and vaccination
BDIX rats were injected i.p. 
CTL assays
Eight-week old BDIX rats received two successive (2 weeks apart) i.p. injections of 10 6 IL-12-or GM-CSF-expressing DHD/K12 cells. CTL assays were performed after a 7-day mixed lymphocyte-tumor cell culture in the presence of human IL-2 (50 U/mL). Briefly, mesenteric and cervical lymph nodes and spleens were aseptically removed at 1 and 3 weeks after the second vaccination. Single-cell suspensions were prepared from lymph nodes and spleens by mechanical dissociation and filtration. Erythrocytes were lysed from spleen cells suspended in NH 4 Cl 0.9% for 30 minutes at 4°C. After washing, spleen cells were suspended in complete medium and irradiated (1000 rad). A total of 12.5 ϫ 10 6 lymph node cells were restimulated for 7 days in vitro with 12.5 ϫ 10 6 irradiated spleen cells and 2.5 ϫ 10 6 irradiated (16,000 rad) DHD/K12 parental cells in complete medium supplemented with 50 U/mL human IL-2.
The CTL assay was performed against either DHD/K12 or UMR 106-01 target cells labeled with sodium ( 51 Cr) dichromate for 1 hour at 37°C. Target cells (5 ϫ 10 3 cells/well) were incubated in 96-well microtiter plates either alone (to determine the spontaneous release (S) of 51 Cr), with effector cells at effector to target cell ratios of 100:1, 50:1, 25:1, 12.5:1, 6.25:1, and 3.12:1 to measure the induced 51 Cr release (I), or with cells lysed in detergents to determine the maximum release (M). Each culture was performed in triplicate. After a 4-hour incubation at 37°C, plates were centrifuged, supernatants were harvested, and the released radioactivity was measured in a ␥-counter. The lymphocyte-induced cytotoxic effect was calculated according to the following formula: ([I Ϫ S]/[M Ϫ S]) ϫ 100. Nonspecific cytotoxicity was defined against the allogeneic UMR 106-01 cell line; specific CTL activity was defined as the cytotoxic activity against NK-resistant autologous DHD/K12 tumor cells.
RESULTS
Retrovirus-producing cell lines
In this study, we used the FLYA13 packaging cell line, which has been described as a highly efficient retrovirus producing cell line that generates high titers of retroviruses resistant to inactivation by human sera. 26 Two packaging cell lines were engineered, FLYA13 IL-12 and FLYA13 GM-CSF, by transfection with a retroviral vector (MoMuLV-derived) expressing mIL-12 p40 and p35 or mGM-CSF, respectively. Using G418 resistance as a marker, we measured the number of retroviral particles produced by the different cell lines and reproducibly found a titer of 10 4 plaque-forming units/mL for FLYA13 IL-12 cells and 10 5 plaque-forming units/mL for FLYA13 GM-CSF cells.
Infection of tumor cell lines
Rat DHD/K12 colorectal adenocarcinoma cells were infected with recombinant retroviruses containing the DNA sequence encoding mGM-CSF or mIL-12 as described previously for DHD/K12 cells expressing the TK gene. 25 Stably transfected DHD/K12 IL-12 cells secreted 40 ng of mIL-12/10 6 cells/48 hours, whereas DHD/K12 GM-CSF cells secreted 30 ng of mGM-CSF/10 6 cells/48 hours. The levels of expression of mGM-CSF or mIL-12 were stable over several passages and after a freezethawing cycle. After ␥ irradiation, levels of cytokine expression by both cell lines decreased dramatically before returning to initial levels by day 4 (data not shown). Delayed tumor progression after simultaneous injection of DHD/K12 parental cells with IL-12-but not with GM-CSF-secreting DHD/K12 cells BDIX rats were injected i.p. with untransduced DHD/ K12 cells alone or mixed with different proportions of DHD/K12 cells expressing IL-12 or GM-CSF (Fig 1) .
DHD/K12 GM-CSF cells did not have any effect on (Fig 2) . Preinjection with irradiated cytokine-producing cells did not protect animals against a subsequent challenge with DHD/K12 parental cells (data not shown).
However, vaccination with proliferating engineered cells was effective. Indeed, tumor growth was delayed and the survival time was significantly increased in all groups compared with control animals (log-rank test: P Ͻ .01). The best protective effect seemed to be afforded by GM-CSF-expressing DHD/K12 cells, with 20% of the animals remaining tumor-free at day 250; however, this advantage over IL-12-secreting DHD/K12 cells failed to reach significance (Fig 2) .
Therefore, preimmunization with a single injection of 10 6 DHD/K12 IL-12 or DHD/K12 GM-CSF cells elicited a systemic immune memory against tumor parental cells and partially protected the animals against a subsequent challenge with parental DHD/K12 cells.
The association of DHD/K12 IL-12 and DHD/K12 GM-CSF cells in the same inoculum did not generate further benefit in comparison with each cell type alone.
CTL responses in animals injected with IL-12-or GM-CSF-producing DHD/K12 cells CTL responses against DHD/K12 autologous and UMR 106-01 allogeneic cell lines were evaluated in BDIX rats preimmunized with two successive (2 weeks apart) i.p. injections of IL-12-or GM-CSF-expressing DHD/K12 cells. CTL assays were performed at 1 and 3 weeks after the second injection. Non-vaccinated BDIX rats were used as a controls (Fig 3) .
Mixed lymphocyte-tumor cell culture generated a significant CTL activity against DHD/K12 cells only in animals preimmunized with GM-CSF-expressing DHD/ K12 cells. To determine the specificity of this activity, an allogeneic cell line, UMR 106-01, was used as a target. No differences in UMR 106-01 cell killing were found between the three groups, indicating that specific CTL lysis of DHD/K12 cells was a result of the vaccination with GM-CSF-expressing cells. Thus, our study demonstrated that a specific, longlasting immune reaction can be elicited through cytokine gene expression against poorly immunogenic colorectal carcinoma cells. Indeed, very few studies have investigated vaccination against colorectal tumors. Subcutaneous immunization with 10 6 irradiated (16,000 rad) DHD/ K12 Prob cells had no effect on subsequent tumor growth. 19 However, another vaccination assay performed in the same model 20 showed that subcutaneous injection of DHD/K12 IL-2-proliferating cells or DHD/ K12 irradiated cells treated previously with sodium butyrate partially protected the animals against a subsequent challenge with DHD/K12 parental cells. In the same study, DHD/K12 IL-2 irradiated cells or DHD/K12 irradiated cells plus BCG did not provide protection. Moreover, BDIX rats bearing i.p. DHD/K12-induced tumors that responded to a treatment with sodium butyrate and high doses of IL-2 developed immune protection against a challenge with the same cell line, confirming that an immune response can be induced against DHD/K12 cells. 19 Our study also indicated that the i.p. route is suitable for immunizing animals against cancer cells. Moreover, these animals are protected against i.p. cancer dissemination, a situation that is frequently encountered in human ovarian and digestive neoplasms.
DISCUSSION
The two cytokines tested, IL-12 and GM-CSF, inhibited DHD/K12 in vivo tumorigenicity and induced immune protection against a tumor challenge. However, their mechanisms of action are quite different: GM-CSF acts through APC maturation and recruitment, whereas IL-12 stimulates interferon-␥ secretion, induces NK and T-cell cytotoxicity, and supports the differentiation of Th1 cells. Indeed, the two cytokines had distinct effects in our experiments. When simultaneously injected with DHD/K12 parental cells, IL-12-expressing cells delayed tumor progression, whereas GM-CSF-expressing cells did not. Colombo et al 7 previously described the same phenomenon. C26 colon adenocarcinoma cells expressing GM-CSF were not tumorigenic, but tumors arose in 100% of the animals injected with C26 GM-CSF/C26 mixtures. One may hypothesize that GM-CSF acting through APC maturation and recruitment needs a latency period, which authorizes tumor cell proliferation, thereby overriding the immune response. Thus, it seems that GM-CSF does not have any direct effect on tumor cells, but generates a specific systemic immune response. In contrast, IL-12 cells might generate a rapid, nonspecific immune response against tumor cells, maybe through the activation of NK cells. Moreover, IL-12 also inhibits angiogenesis, indicating a broad range of anticancer activities. 27 Both cytokines were able, when expressed by tumor cells, to induce a specific and long-lasting immune response, as demonstrated by the resistance against a tumor challenge. However, under our experimental conditions, in vitro CTL activity against parental DHD/K12 cells could only be observed after GM-CSF vaccination. Vaccination with IL-12-secreting cells could preferentially induce cytolytic effectors with slow killing mechanisms (i.e., involving Fas ligand) not detected in the standard 51 Cr release assay. These data suggested that, in our model, IL-12 acts through two distinct pathways, generating a nonspecific, rapid effect on tumor cells and a specific, systemic immune response.
As the two cytokines act through distinct immunological pathways, we hoped that they could synergize. However, mixing DHD/K12 IL-12 and DHD/K12 GM-CSF cells in the same vaccine did not lead to better protection in comparison with administration of a single engineered cell line. Therefore, we could not observe any synergy between GM-CSF and IL-12 in our model. Moreover, we have also failed to observe any similar synergy when GM-CSF and IL-12 retrovirus-producing cells were administered together with the TK gene in a therapeutic approach for peritoneal carcinoma in the same model (C.L. unpublished data). However, we cannot rule out that such a lack of synergy was due to a smaller number of cells producing each cytokine and thus to the production of lower amounts of the cytokines. Indeed, others have previously demonstrated a dose-response relationship between GM-CSF or IL-12 secretion and the immune response, 2,17 and we did not observe any protection with irradiated cells, which produced lower levels of cytokines. In conclusion, although we failed to demonstrate synergistic antitumoral immune stimulation by IL-12 and GM-CSF, further studies will have to be performed to investigate whether it is beneficial to act simultaneously on antigen presentation and on NK and Th1 immune responses. These studies will have to choose appropriate vectors to obtain high simultaneous local levels of both cytokines.
Thus, it is possible to elicit a specific antitumoral immune response directed against colorectal carcinoma cells. Active immunotherapy may be useful as an adjuvant therapy after surgical resection of a tumor for many reasons. First, several studies have demonstrated that surgical manipulations of a tumor always liberate circulating cancer cells, which may cause micrometastases. 28 , 29 Liefers et al 30 recently correlated the molecular detection of lymph node micrometastases in patients with stage II colorectal cancer with a high risk for tumor recurrence, indicating the importance of eliminating residual cancer cells. Second, surgical wounds usually induce a transient immunodepression and altered cytokine expression, which allows cancer cells to escape the immune system. [31] [32] [33] In conclusion, our data suggest that specific antitumoral immunization before surgery for colorectal carcinoma might allow a specific antitumoral immune response and be efficient against micrometastases and circulating tumor cells.
